Martha Louzada

Identification of broadly tumour-reactive γδ TCRs from multiple myeloma

Michael St. Paul, Liam D. Hendrikse, Fan Ying, Bryan E. Snow et autres

γδ T cells are becoming increasingly appreciated for their antitumour capacity and role in mediating responses to immune checkpoint blockade1–3. Unlike classical αβ T cells, the degree to which γδ T cells rely on their T cell receptors (TCRs) to induce antitumour …

ca, hk (code pays fourni par la source)

Real-world outcomes of patients with multiple myeloma who reach third-line therapy: a Canadian report

Martha Louzada, DE Reece, Christopher P. Venner, Darrell White et autres

Multiple myeloma (MM) remains an incurable cancer and is characterized by a remitting-relapsing pattern. The choice of next line of therapy depends on patient-, disease-, and treatment-related factors. The Canadian Myeloma Research Group database (CMRG-DB) hosts information in ≥10 000 individuals with …

ca (code pays fourni par la source)

Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Julia Varghese, Christopher P. Venner, Martha Louzada, Donna Reece et autres

ca (code pays fourni par la source)

Head-to-head longitudinal comparison of two mass spectrometry-based methods for monitoring monoclonal proteins in multiple myeloma: Analytical and clinical insights from the GEM-CESAR trial

Noemí Puig, Matthew Nichols, Cristina Agulló, S. Castro et autres

Abstract Background: Mass spectrometry (MS) is increasingly used to detect monoclonal proteins (MPs) in patients with monoclonal gammopathies. Two major intact light chain approaches—MALDI-TOF (Exent) and LC-Q/TOF—have shown superior sensitivity over conventional methods. However, direct comparisons between them are lacking, limiting their …

es, ca, gb (code pays fourni par la source)

Real-world experience with first-line regimens in transplant-ineligible patients with multiple myeloma

Danyal Ladha, Donna Reece, Guido Lancman, Arleigh McCurdy et autres

Abstract Introduction Regimens based on bortezomib and lenalidomide have been a mainstay of treatment for transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM) patients (pts). Recently, the phase 3 MAIA trial established DRd as the new standard of care (SoC), with a median …

ca (code pays fourni par la source)

Real-world outcomes of teclistamab for multiple myeloma in Canada: Multi-institutional report from the Canadian myeloma research group (CMRG) database

Guido Lancman, Donna Reece, Arleigh McCurdy, Engin Gul et autres

Abstract Introduction: Teclistamab is a highly effective treatment for relapsed multiple myeloma (MM), with an overall response rate (ORR) of 63% and progression-free survival (PFS) of 11.4 months in the MajesTEC-1 trial. real-world data are needed to understand outcomes in a broader …

ca, gb, us, jp, au (code pays fourni par la source)

Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database

Rayan Kaedbey, Christopher P. Venner, Donna Reece, Kevin A. Hay et autres

ca (code pays fourni par la source)

Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL)

Imran Haider, Darryl P. Leong, Martha Louzada, Arleigh McCurdy et autres

ie, ca, us (code pays fourni par la source)

Shortcoming of serum B-cell maturation antigen measurement by enzyme-linked immunosorbent assay in one laboratory’s experience: Unsatisfactory assay reproducibility

Ian Cheong, Christopher Liang, Vipin Bhayana, Ivan Stevic et autres

ca (code pays fourni par la source)

Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis

Arleigh McCurdy, Engin Gul, Donna Reece, Michael P. Chu et autres

ca (code pays fourni par la source)

Real-World Outcomes in Myeloma Patients with T (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

Julia Varghese, Christopher P. Venner, Martha Louzada, Donna Reece et autres

ca, in (code pays fourni par la source)

Enhanced detection and Characterization of M-proteins in multiple myeloma patients using An Agilent AssayMAP Bravo liquid handling system coupled to an LC-QTOF

Matthew Nichols, Chai W. Phua, Martha Louzada, Benjamin D. Hedley et autres

ca (code pays fourni par la source)